ECCO News

ECCO News keeps ECCO Members up-to-date on what is going on within the organisation and reports on IBD activities taking place within Europe. Since Spring 2006, ECCO News has maintained the flow of information between Members of the organisation. 

ECCO News is an important part of the European Crohn’s and Colitis Organisation’s ambition to create a European standard of IBD care and to promote knowledge and research in the field of IBD. ECCO Members automatically receive this publication four times a year. 

Associate Editors


Nuha Yassin
© ECCO

Ignacio Catalán-Serra
© Ignacio Catalán-Serra

Latest ECCO News Content


15December2020

Y-ECCO Members’ Address

Johan Burisch, Y-ECCO Chair

Johan Burisch
© ECCO

Dear Y-ECCO Friends,

I hope you had a nice UEG Week Virtual earlier in October. My experience with the many virtual symposia over recent months has been mixed, but I think that the virtual UEG Week worked very well, with great interactions from viewers and excellent lectures. Hopefully, we’ll be able to attend the ECCO Congress next year in person – I’m sure that you miss interacting with friends and colleagues as much as I do. But the experience at UEG Week makes me optimistic that this format can also work well.

Posted in ECCO News, Committee News, Volume 15, Issue 4, Y-ECCO

15December2020

How to get the best out of your pathologist

Francesca Rosini, H-ECCO Member

Francesca Rosini 
© ECCO

The histological diagnosis of Inflammatory Bowel Disease (IBD) is not an easy task for a pathologist. In the modern era, personal pathology experience alone is insufficient to make a diagnosis of IBD. The information that a pathologist must know in order to evaluate IBD samples appropriately and to make a diagnosis is diverse, and for the most part should be provided by the gastroenterologists, surgeons or clinicians responsible for the care of patients. Even the most experienced pathologist cannot report a case without knowing the clinical background of the patient. Obviously, this should be the standard for all samples, not only for IBD.

Posted in ECCO News, Committee News, Volume 15, Issue 4, H-ECCO

15December2020

COVID-19 and Paediatric Inflammatory Bowel Disease

David Wilson, P-ECCO Chair

David Wilson
© ECCO

Since the first reports in Wuhan, China in December 2019, the new coronavirus SARS-CoV-2 has resulted in over 40 million confirmed cases of COVID-19 globally with over 1 million deaths within just 10 months. Economies have been shattered, routine healthcare has been severely disrupted, and restrictions have been imposed on travel and social and family life in a previously unthinkable manner.

Posted in ECCO News, Committee News, Congress News, Volume 15, Issue 4, P-ECCO

15December2020

High Performance in IBD Surgery

Omar Faiz, S-ECCO Member

Omar Faiz
© ECCO

High performance in surgery has been the subject of discussion for a number of years. In IBD surgery it’s been what you might call a ‘shaggy dog’ story. For those of you unfamiliar with this term – there is an entire Wiki page dedicated to it [1]. High performance in IBD surgery has, thus far, fulfilled the criteria for such a story perfectly – it’s: long-winded, anecdotal, arguably failed to reach relevance and a bit of an anti-climax – all the essential ingredients.

Posted in ECCO News, Committee News, Volume 15, Issue 4, S-ECCO

15December2020

Nutritional Management of Iron Deficiency

Catherine Wall, D-ECCO Member

Catherine Wall
© ECCO

Iron deficiency and iron-deficiency anaemia (IDA) are characterised by fatigue and reduced capacity for normal activities of daily living and consequently poorer quality of life. Iron deficiency is estimated to affect 60%–80% of people with IBD at some point [1]. Recurrent iron deficiency is also common and is estimated to occur in 30% of patients [1]. Given the prevalence of iron deficiency, some patients and practitioners have learned to accept this impaired quality of life as an unavoidable consequence of IBD [2]. However, correction of iron deficiency in patients without anaemia can result in improved quality of life and less fatigue and should, therefore, be an important treatment goal.

Posted in ECCO News, Committee News, Volume 15, Issue 4, D-ECCO

15December2020

N-ECCO Opportunities at the 16th Congress of ECCO

Ana Ibarra, N-ECCO Member


Ana Ibarra 

© ECCO

Once again, N-ECCO is offering an outstanding range of clinical and educational opportunities for nurses attending the ECCO’21 Copenhagen Congress.

The programmes for each activity continue to be developed on the basis of the evaluation forms from the previous year in order to meet your needs. Thank you so much for providing your feedback, which helps us to improve all the N-ECCO Activities.

Posted in ECCO News, Committee News, ECCO'21, Volume 15, Issue 4, N-ECCO

15December2020

GRADE Workshop at ECCO'21

Tim Raine, GuiCom Member

Tim Raine 
© ECCO

Previous participants in GuiCom workshops at recent ECCO Congresses will have learned much about the adoption of GRADE methodology into the ECCO Guideline process and the practicalities of working with the GRADE process. For ECCO 2021, GuiCom wanted to offer participants something a little different. The GuiCom 2021 Workshop will therefore seek to place the GRADE process within the current controversies and ‘hot topics’ with respect to guidelines.

Posted in ECCO News, Committee News, GuiCom, Volume 15, Issue 4

15December2020

The exposome and personalised medicine in IBD

Behrooz Z. Alizadeh, EpiCom Member

Berhooz Z. Alizadeh 
© ECCO

Introduction

In the past few decades, the incidence of Inflammatory Bowel Diseases (IBD) started rising especially in industrialised Western countries, affecting more than two million Americans and Europeans [1–3]. At the turn of the twenty-first century, however, IBD became a global disease, rapidly affecting the Eastern and Southern developing nations [3–5]. So, the global prevalence of IBD is currently estimated at 0.7% and is expected to increase to 1% by 2030 [1, 3, 6].The rise in IBD has coincided with an increase in urbanisation, sanitisation, and adoption of a Western lifestyle [4], as well as advances in infrastructure, better access to healthcare, and increased awareness of community following socioeconomic development. It is therefore assumed that the primary suspect underlying the globalisation of IBD is the alteration of the human environment, called the exposome (meaning exposures to environmental and lifestyle factors throughout life, starting at conception), and the associated embracing of Western lifestyles by other nations [6].

Posted in ECCO News, Committee News, Volume 15, Issue 4, EpiCom

15December2020

How should IBD clinical research evolve in the COVID era?

Laurent Beaugerie, ClinCom Member


Laurent Beaugerie
© ECCO

 An interview with Gionata Fiorino

During this period when we are so tormented by the SARS-CoV-2 pandemic, Gionata Fiorino, from Humanitas Research Hospital in Milan, agreed to give us his views on the challenges of adapting IBD clinical research.

Posted in ECCO News, Committee News, ClinCom, Volume 15, Issue 4

15December2020

ECCO Grant Study Synopsis: Sebastian Zundler

Sebastian Zundler, ECCO Grant Awardee

Dose-related differential effects of vedolizumab on leukocyte subsets


Sebastian Zundler
© Sebastian Zundler

Aim of research

The anti-α4β7 integrin antibody vedolizumab is successfully used for the clinical treatment of IBD. However, some details of its mechanisms are still not clear. Moreover, whether dose intensification of vedolizumab therapy may also increase response rates is the subject of ongoing debate, as some previous studies have suggested a non-linear exposure–efficacy correlation. Since only a portion of patients benefit from vedolizumab therapy, further translational insights into these aspects are an important unmet need for therapy optimisation and the development of personalised treatment approaches.

Based on preliminary data we hypothesise that vedolizumab has a differential preference of binding to distinct leukocyte subsets (e.g. effector and regulatory T cells), resulting in specific profiles of targeted immune cells at a certain level of vedolizumab exposure. This may explain the suggested non-linear exposure–efficacy correlation.  Therefore, we aim to elucidate dose-dependent binding characteristics to leukocyte subsets and related functional aspects in vitro and in vivo.

Posted in ECCO News, Committee News, SciCom, Fellowships & Grants Synopsis Reports, Volume 15, Issue 4

Portal

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.